The trade war between the United States and China has lasted for more than one year — and a resolution is nowhere in sight.World Economyread more
The Fed is expected to cut rates Wednesday, but it is unlikely to tell markets what they want to hear on future rate cuts.Market Insiderread more
Pelosi said Trump should not have tried to address China's trade practices in a way that opened Americans up to financial pain.Politicsread more
Investors await the Fed's latest decision on monetary policy, set to be released on Wednesday stateside. The U.S. central bank is widely expected to cut rates by 25 basis...Asia Marketsread more
TransferWise posted an annual net profit of £10.3 million on revenues of £179 million.Technologyread more
Live the high life with a night's stay at Highclere Castle, the iconic stately home made famous by Downton Abbey.Spendread more
Large banking institutions face the risk of failure if interest rates in Europe continue to stay negative, warns the global chief economist of the Economist Intelligence Unit.Banksread more
The fallout from two fatal crashes of Boeing 737 Max planes has ensnared the manufacturer's most-loyal customer: Southwest Airlines. The carrier has canceled thousands of...Airlinesread more
Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
In the survey, conducted after the third in the Democratic Party's series of debate, the former vice president draws 31% compared to 25% for the Massachusetts senator. At 14%,...2020 Electionsread more
Stocks rose slightly on Tuesday, but gains were capped as the Federal Reserve kicked off a two-day monetary policy meeting.US Marketsread more
Upon the release of BioMarin's orphan drug Brineura, which made headlines for its $702,000-per-year price tag, chairman and CEO JJ Bienaimé said the system will have the final say on whether the sky-high price is fair.
"Obviously, the system will have to determine that," he told "Mad Money" host Jim Cramer on Friday. But I would say that CLN2, the disease that Brineura is being used for, is an absolutely devastating neurodegenerative disorder for which, unfortunately, the patients will lose their life, most of the time by [age] 12."
CLN2, also known as Batten disease, affects between 1,200 and 1,500 patients worldwide, with 20 new patients a year in the United States.
Watch the full segment here:
Because the disease starts with unexplained seizures, many patients are misdiagnosed as being epileptic. By the age of 7 or 8, most lose their ability to walk, talk and see, and Brineura is currently the only approved drug for treating the disorder.
As most affected patients are on federally funded programs like Medicaid, mandatory government discounts brings the drug's price down to $486,000.
The discounts do not take the drug's cost out of the stratosphere, but Bienaimé said that the rarity of the disease makes medication extremely costly and complicated to produce.
"The cost of manufacturing Brineura per year is north of $100,000 per year per patient," he told Cramer, adding that efforts are underway at BioMarin to offer free genetic tests for young patients with unexplained seizures.
The CEO added that all of the drugs BioMarin produces, most of which are for diseases that are genetic and have no available treatments, are highly risky to develop.
"Nine out of 10 drugs that get into clinical development, that means being tried in humans, never make it to the market, so the failure rate is extremely high," he told Cramer.
That drives up operational costs, which end up being reflected in drug pricing. And although Washington lawmakers have knocked pharmaceutical companies for high drug costs, Bienaimé said most policymakers understand the industry's inevitable trial-and-error aspects.
"I think, hopefully, ... if there is any kind of regulations coming around health care, that they will make sure that those regulations protect innovation and protect innovative biotech companies," Bienaimé said. "And biotechnology is one of the only left industries where the U.S. is a leader in the world and we hope it will stay that way."
Questions for Cramer?
Call Cramer: 1-800-743-CNBC
Questions, comments, suggestions for the "Mad Money" website? email@example.com